Sente Inc., Appoints Mireille Gillings, Ph.D. to Its Board of Directors

Experienced Biopharmaceutical Industry Executive Adds to the Depth of the Company's Board

SAN DIEGO, June 17, 2014 (GLOBE NEWSWIRE) -- Sente Inc., a privately held specialty aesthetics company pioneering the development of differentiated medical skincare products based on the science of glycoproteins, announced today that it has appointed Mireille Gillings, Ph.D. to its Board of Directors. Dr. Gillings is Sente's sixth director and brings additional biotechnology industry operations and management experience to the Sente Board of Directors.

Dr. Gillings has more than 20 years experience in the biotechnology industry and is a published academic in the field of neuroscience. In 2004 she founded HUYA Bioscience International and has since grown this privately-held company to become the global leader in accelerating the co-development of biopharmaceutical product opportunities originating in China. Dr. Gillings was the first to establish extensive collaborations with Chinese academic and commercial biopharmaceutical organizations to create value in worldwide markets for China-sourced novel biopharmaceutical compounds.

Dr. Gillings is a board member of Quintiles, a Fortune 500 company; the vice-chair and co-founder of GHO Capital, a private equity fund specialized in global health; and also serves on the Pasteur Institute Advisory Board. She completed post-doctoral fellowships at Bordeaux University, Scripps Research Institute and holds a Ph.D. from Radboud University Nijmegen.

"We are extremely pleased to have Mireille join our Board during this exciting stage of the company's growth," said Faheem Hasnain, Chairman of the Board of Directors of Sente, Inc. "Given Mireille's extensive knowledge and proven track record in the development of biotechnology companies, she will be a valuable addition to the Sente Board."

"I am delighted to be associated with Sente's impressive Board of Directors and management team and I share the commitment to build a leading science based aesthetic skin care company," said Mireille Gillings, Ph.D. "The proprietary heparan sulfate technology and the impressive customer results clearly differentiate Sente within the growing aesthetic market."

About Senté, Inc.

Senté, Inc. is a privately held specialty aesthetics company leveraging its expertise and foundation in biotechnology to deliver novel, science-based skin care products. Senté is a recognized leader in the development of innovative and targeted medical skincare products based on glycoproteins. Senté recently launched its first physician dispensed dermatological product, Senté Dermal Repair Cream, which is currently the only aesthetic product utilizing low molecular weight heparan sulfate on the market today. HS is the most biologically active of the glycoproteins that reside naturally in human skin, and is responsible for regulating a wide variety of biological activities within the body. The biologically active glycoproteins used in Senté Dermal Repair Cream help increase skin hydration, gradually lighten the appearance of pigmented lesions and soothe irritated skin. Founded in 2007 and based in San Diego, California, further information may be found at  Sente products are available through our exclusive network of physicians, medically supervised spas and through


Contact Data